Jiangsu Recbio receives UAE approval to initiate phase II/III study of sequential booster vaccination for Covid-19 vaccine, ReCOV

Jiangsu Recbio Technology Co., Ltd., an innovative vaccine company, announced that the company has received approval from the Ministry of Health and Prevention of the United Arab Emirates (UAE) (Clinical Trial Approval) to conduct a phase II/III clinical study of sequential booster vaccination for its recombinant protein Covid-19 vaccine ReCOV (ReCOV) to evaluate the immunogenicity and safety of ReCOV as a heterologous booster in adult subjects. This clinical trial is a multi-centre, randomized, observer-blinded, active-controlled phase II/III study on persons who have previously completed two doses of inactivated Covid-19 vaccine for primary vaccination and whose last vaccination is 3 to 12 months away from heterologous booster of ReCOV. It is expected that approximately 1,950 adult subjects will be enrolled. The study's safety and immunogenicity data are expected to be published in 2022, supporting the submission to the UAE Emergency Use Authorization (EUA) for ReCOV as a heterologous booster. In May 2020, Recbio, together with Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu CDC) and Taizhou Medical New & High-tech Industrial Development Zone, jointly developed a recombinant two-component Covid-19 vaccine(ReCOV). Under the guidance of Professor Fengcai Zhu from the Jiangsu CDC, the R&D team thoroughly optimized the vaccine using protein engineering and new adjuvant technologies, so that ReCOV has promising safety and strong immunogenicity against SARS-CoV-2 and variants of concern such as Omicorn and Delta. A series of comprehensive advantages such as better cross-protection against emerging variants, easy scale-up of production, cost advantages, worldwide accessibility, good preparation stability, and storage and transportation at room temperature which become a very competitive second-generation new Covid-19 vaccine. Founded in 2012, Recbio is an innovative vaccine company. With the vision of "Become the Leader of Innovative Vaccine in the Future," Recbio takes "Protect Human Health with Best-in-Class Vaccines" as its mission. It has established three major cutting-edge technology platforms including novel adjuvants platform, protein engineering platform, immunological evaluation platform and mRNA vaccine platform.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!